Publications by authors named "Amitkumar Mehta"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

65,705

Total Likes

909

Extended Reach

483,144

Social Features

19
L
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis

September 2020

Videos about Article: user user

2 17 4 16

View All Article and Social Media Activity
N
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.
Nathalie A Johnson, Pier Luigi Zinzani, Eva Domingo-Domenech, Joshua Brody, Justin Kline, Amitkumar Nitinkumar Mehta

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.
Yucai Wang, Melissa C Larson, Steven R Hwang, Diego Villa, Laveniya Kugathasan, Amitkumar Nitinkumar Mehta

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.
Sarit E Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B Johnston

Clin Lymphoma Myeloma Leuk· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.
Sunandini Sharma, Roshia Ali, Alyssa Bouska, Dylan Jochum, Meghana Kesireddy, Amitkumar Mehta

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
Carrie Thompson, Marek Trněný, Franck Morschhauser, Gilles A Salles, Patrick M Reagan, Amitkumar Mehta, Neha Mehta-Shah

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study.
Pamela B Allen, Subir Goyal, Swaminathan Iyer, Sai Talluru, Auris Huen, Amitkumar Mehta

J Am Acad Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study.
Jason Westin, Tycel J Phillips, Amitkumar Mehta, Marc S Hoffmann, Eva Gonzalez-Barca

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.
Mohamed A Kharfan-Dabaja, Razan Mohty, Neela Easwar, Patrick Johnston, Madiha Iqbal, Amitkumar Mehta

Bone Marrow Transplant· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall and Cause-Specific Mortality Among Patients With Cutaneous T-Cell Lymphoma in the United States.
Lauren Shea, Mayur Narkhede, Karthik Chamarti, Tina Gao, Amitkumar Mehta

EJHaem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.
Amitkumar Mehta, Leslie Popplewell, Graham P Collins, Sonali M Smith, Ian W Flinn

Blood Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Joseph E Maakaron, Adam Asch, Leslie Popplewell, Graham P Collins, Ian W Flinn, Amitkumar Mehta

Blood Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Pier Luigi Zinzani, Gilles Salles, Alison J Moskowitz, Armando Santoro, Amitkumar Mehta, Neha Mehta-Shah

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Christopher R Flowers, Matthew J Matasar, Alex F Herrera, Mark Hertzberg, Sarit Assouline, Amitkumar Mehta

Haematologica· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Michael Wang, Tanya Siddiqi, Leo I Gordon, Manali Kamdar, Matthew Lunning, Amitkumar Mehta

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Tycel J Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Amitkumar Mehta

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Lihua E Budde, Adam J Olszewski, Sarit Assouline, Izidore S Lossos, Catherine Diefenbach, Amitkumar Mehta

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
James N Gerson, Elizabeth Handorf, Diego Villa, Alina S Gerrie, Parv Chapani, Amitkumar Mehta

Blood Adv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Amitkumar Mehta

J Hematol Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
Sydney Dunn-Valadez, Srilakshmi Bathini, Kathleen E Purdy, Kimo Bachiashvili, Ravi Bhatia, Amitkumar Mehta

Leuk Lymphoma· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, Philippe Armand, Tae Min Kim, Amitkumar Mehta

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski, Amitkumar Mehta

EClinicalMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, Weimin Liu, Regina M Stoltz, Amitkumar Mehta

PLoS Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta

J Immunother Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding access to early phase trials: the CATCH-UP.2020 experience.
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, Anthony F Shields, Farshid Dayyani, Amitkumar Mehta

JNCI Cancer Spectr· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia.
Kai Qin, Kazuhito Honjo, Scott Sherrill-Mix, Weimin Liu, Regina Stoltz, Amitkumar Mehta

medRxiv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis